REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

Data ReadoutSurabgene LomparvovecNeutral

AI Analysis

Summary

REGENXBIO announced an investor event on October 20, 2026 to discuss its surabgene lomparvovec clinical program for wet AMD ahead of anticipated topline pivotal data in 4Q 2026. The event will include clinical program overview and perspectives from retina specialists.

Clinical Trial Data

Phase

Phase_3

Outcome Details

Topline pivotal data readout anticipated in 4Q 2026

Importance:5/10

Sentiment:

0.00

investor eventwet AMDgene therapypivotal trialdata readout

Related Companies

$RGNX

Read the original article

Published by PR Newswire Biotech on October 12, 2026 11:05 AM

Read Original